Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
Public ClinicalTrials.gov record NCT04112095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use (ACCESS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
Study identification
- NCT ID
- NCT04112095
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 962 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 11 Years and older
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2019 (Actual)
- Primary completion
- Aug 5, 2021 (Actual)
- Completion
- Aug 5, 2021 (Actual)
- Last update posted
- May 20, 2022
2019 – 2021
United States locations
- U.S. sites
- 38
- U.S. states
- 17
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HRA Pharma Investigational site 1012 | Birmingham | Alabama | 35215 | — |
| HRA Pharma Investigational Site 1008 | Homewood | Alabama | 35209 | — |
| HRA Pharma Investigational Site 1038 | Mesa | Arizona | 85203 | — |
| HRA Pharma Investigational Site 1032 | Phoenix | Arizona | 85021 | — |
| HRA Pharma Investigational Site 1027 | Cerritos | California | 90703 | — |
| HRA Pharma Investigational Site 1039 | Downey | California | 90242 | — |
| HRA Pharma investigational site 1035 | Long Beach | California | 90806 | — |
| HRA Pharma Investigational Site 1017 | Long Beach | California | 90815 | — |
| HRA Pharma Investigational Site 1034 | Los Angeles | California | 90005 | — |
| HRA Pharma Investigational Site 1029 | Los Angeles | California | 90036 | — |
| HRA Pharma Investigational Site 1028 | Los Angeles | California | 90057 | — |
| HRA Pharma Investigational Site 1033 | Aurora | Colorado | 80045 | — |
| HRA Pharma Investigational Site 1023 | Dalton | Georgia | 30721 | — |
| HRA Pharma Investigational Site 1018 | Griffin | Georgia | 30224 | — |
| HRA Pharma Investigational Site 1014 | Rosedale | Maryland | 21237 | — |
| HRA Pharma Investigational Site 1019 | Framingham | Massachusetts | 01702 | — |
| HRA Pharma Investigational Site 1011 | Andover | Minnesota | 55304 | — |
| HRA Pharma Investigational Site 1006 | Elk River | Minnesota | 55330 | — |
| HRA Pharma Investigational Site 1003 | Saint Francis | Minnesota | 55070 | — |
| HRA Pharma Investigational Site 1020 | Saint Louis Park | Minnesota | 55426 | — |
| HRA Pharma Investigational Site 1009 | Albuquerque | New Mexico | 87104 | — |
| HRA Pharma Investigational Site 1007 | Albuquerque | New Mexico | 97110 | — |
| HRA Pharma Investigational Site 1030 | Bronxville | New York | 10708 | — |
| HRA Pharma Investigational Site 1013 | New York | New York | 10034 | — |
| HRA Pharma Investigational Site 1037 | The Bronx | New York | 10463 | — |
| HRA Pharma Investigational Site 1031 | The Bronx | New York | 10467 | — |
| HRA Pharma Investigational Site 1015 | Burlington | North Carolina | 27215 | — |
| HRA Pharma Investigational Site 1002 | South Charleston | Ohio | 45368 | — |
| HRA Pharma Investigational Site 1036 | Lafayette Hill | Pennsylvania | 19444 | — |
| HRA Pharma Investigational Site 1025 | Philadelphia | Pennsylvania | 19136 | — |
| HRA Pharma investigational site 1016 | Clarksville | Tennessee | 37043 | — |
| HRA Pharma Investigational Site 1022 | Houston | Texas | 77008 | — |
| HRA Pharma Investigational Site 1001 | Houston | Texas | 77099 | — |
| HRA Pharma investigational site 1024 | Mapleton | Utah | 84664 | — |
| HRA Pharma Investigational Site 1040 | Salt Lake City | Utah | 84101 | — |
| HRA Pharma Investigational Site 1021 | Enumclaw | Washington | 98022 | — |
| HRA Pharma Investigational site 1005 | Seattle | Washington | 98117 | — |
| HRA Pharma Investigational site 1010 | Snohomish | Washington | 98290 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04112095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2022 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04112095 live on ClinicalTrials.gov.